IFIBIO HOUSSAY   25014
INSTITUTO DE FISIOLOGIA Y BIOFISICA BERNARDO HOUSSAY
Unidad Ejecutora - UE
artículos
Título:
Inhibition of striatal cholinergic interneuron activity by the Kv7 opener retigabine and the nonsteroidal anti-inflammatory drug diclofenac
Autor/es:
TUBERT, CECILIA; PAZ, RODRIGO MANUEL; ETCHENIQUE, ROBERTO; DÍAZ, ANALÍA LÓPEZ; PAZ, RODRIGO MANUEL; RELA, LORENA; DÍAZ, ANALÍA LÓPEZ; STAHL, AGOSTINA; RELA, LORENA; MURER, MARIO GUSTAVO; STAHL, AGOSTINA; MURER, MARIO GUSTAVO; TUBERT, CECILIA; ETCHENIQUE, ROBERTO
Revista:
NEUROPHARMACOLOGY
Editorial:
PERGAMON-ELSEVIER SCIENCE LTD
Referencias:
Año: 2018 vol. 137 p. 309 - 321
ISSN:
0028-3908
Resumen:
Striatal cholinergic interneurons provide modulation to striatal circuits involved in voluntary motor control and goal-directed behaviors through their autonomous tonic discharge and their firing ?pause? responses to novel and rewarding environmental events. Striatal cholinergic interneuron hyperactivity was linked to the motor deficits associated with Parkinson´s disease and the adverse effects of chronic antiparkinsonian therapy like L-DOPA-induced dyskinesia. Here we addressed whether Kv7 channels, which provide negative feedback to excitation in other neuron types, are involved in the control of striatal cholinergic interneuron tonic activity and response to excitatory inputs. We found that autonomous firing of striatal cholinergic interneurons is not regulated by Kv7 channels. In contrast, Kv7 channels limit the summation of excitatory postsynaptic potentials in cholinergic interneurons through a postsynaptic mechanism. Striatal cholinergic interneurons have a high reserve of Kv7 channels, as their opening using pharmacological tools completely silenced the tonic firing and markedly reduced their intrinsic excitability. A strong inhibition of striatal cholinergic interneurons was also observed in response to the anti-inflammatory drugs diclofenac and meclofenamic acid, however, this effect was independent of Kv7 channels. These data bring attention to new potential molecular targets and pharmacological tools to control striatal cholinergic interneuron activity in pathological conditions where they are believed to be hyperactive, including Parkinson´s disease.